-
ASH CLL Highlights - Promising Advances in Epcoritamab, TP53 Insights, and CHIP Findings - 5 month(s) ago
Akiva Diamond
Hi everyone, I wanted to send one last email highlighting some of my favorite CLL abstracts from this year’s ASH meeting. First, I’d like to…
-
Real-World Treatment Patterns With Pacritinib For Myelofibrosis - 12 month(s) ago
Alan Skarbnik
Dear readers, To round up our myelofibrosis (MF) collection, I am highlighting some abstracts presented at the 2024 ASCO® Annual Meeting and an article discussing…
-
Akiva Diamond
Dear Colleagues, I hope everyone had a productive and enlightening experience at ASH—or at least got to enjoy following along on social media. I would…
-
Alan Skarbnik
Dear readers, Today, I bring you a few more articles on myeloproliferative neoplasms (MPNs) and myelofibrosis (MF). First, I included an interesting observational study suggesting…
-
ASH Highlights: More Emerging Strategies in MRD-Directed CLL Therapy - 6 month(s) ago
Akiva Diamond
Hi everyone, I’m excited to share more of my favorite CLL abstracts from this year’s ASH Annual Meeting. These studies emphasize innovative, MRD-guided approaches in…
-
Alan Skarbnik
Dear readers, This collection provides a few more insights into the management of myelofibrosis (MF). One article discusses the choices of JAK-2 inhibitors, and another…
-
ASH CLL Highlights: Advances in MRD-Guided Therapy and QoL in CLL - 6 month(s) ago
Akiva Diamond
Hi everyone, I’m excited to be back this year to share some of my favorite CLL abstracts from the ASH Annual Meeting. These abstracts highlight…
Lymphoma
Key opinion leaders in hematologic oncology, Akiva Diamond, MD, and Alan Skarbnik, MD, discuss updates and new research in lymphoma.
Experts in this Learning Lab
Dr. Diamond is a lymphoma specialist, a malignant hematologist, and an assistant professor of medicine at Baylor College of Medicine and the Dan L. Duncan Comprehensive Cancer Center in Houston, Texas.
Dr. Skarbnik is director of the Lymphoma and CLL and Immune Effector Cell and Experimental Therapeutics Programs and associate director of the Transplantation and Cellular Therapy Program at the Novant Health Cancer Institute. He is also a clinical assistant professor at the University of North Carolina School of Medicine at Chapel Hill.
Collections